---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-032748"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T21:50:25.560739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026

## Summary
- Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.
- All 18 patients on ERT at baseline withdrawn from ERT and remain off; α-Gal A activity sustained up to 4.5 years.
- Reported eGFR slope compares favorably to Replagal (-2.2), Fabrazyme (-1.5), Galafold (-0.4) in published studies.
- Significant SF-36 quality-of-life improvements: role-physical +14.8, vitality +9.6, bodily pain +9.0 at week 52.
- No preconditioning required; most adverse events grade 1-2; no safety-related discontinuations.

## SEC filing metadata
- accession: 0001628280-25-032748
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/0001628280-25-032748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/sgmo-20250624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-032748
- JSON: https://secwatch.observer/filing/0001628280-25-032748.json
- Plain text: https://secwatch.observer/filing/0001628280-25-032748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.